Clinical drug–drug interaction studies investigating pharmacokinetics and safety of sevabertinib

Le résumé fourni par la source

Sevabertinib (BAY 2927088) is an oral reversible tyrosine kinase inhibitor being developed for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer harboring human epidermal growth factor receptor 2–activating mutations. Three clinical drug–drug interaction studies with sevabertinib were performed to investigate the effects of: (1) the CYP3A4/P-glycoprotein (P-gp) inhibitor itraconazole and the CYP3A4/P-gp inducer carbamazepine on the pharmacokinetics (PK) of sevabertinib (NCT06348888); (2) sevabertinib on the PK of the CYP3A4 substrate midazolam (NCT06360211); and (3) sevabertinib on the PK of the P-gp substrate dabigatran etexilate and the breast cancer resistance protein (BCRP) substrate rosuvastatin (NCT06329895).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.